摘要
目的:观察麦考酚酸酯( mymcophenolatemofetil,MMF)预防移植肾急性排斥的安全性及有效性。方法:40例肾移植病人分为2组,20例[男性12例,女性 8例,年龄(43 ± s 10) a]为治疗组,给予MMF1g, po, bid;另 20例[男性 13例,女性 7例,年龄(45±11) a]为对照组,给予硫唑嘌呤(Aza) 150mp,po, qn。共 6 mo。结果: MMF组急性排斥反应发生率为0,Aza组为2例,2组间差异无显著意义(P>0.05)。2组病人的消化道反应、肝中毒、感染等并发症的发生率的差异无显著意义(P>0.05)。结论:MMF是一种能预防移植肾急性排斥反应的安全、有效的免疫抑制剂。
To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in the prevention of acute rejection in renal transplantation. METHODS: Forty patients after renal transplantation were divided into 2 groups. Twenty Patients (M 12, F 8, age: 43 a± s 10 a) in treatment group received MMF ig, po, bid, and the other 20 patients (M 13, F 7, age 45 a ± 11 a) received azathioprine (Aza) 150 mg, po, qn, as control. The study lasted for 6 mo. RESULTS: The incidence of acute rejection of MMF group was 0, and of Aza group was 10%, no significant difference was found between the 2 groups (P > 0. 05 ). Side effects in digestive system, liver, and including infections were similar in 2 groups (P > 0. 05 ). CONCLUSION: MMF is an effective and safe immunosuppressant for prevention of acute rejection in renal transplantation.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2000年第1期44-45,共2页
Chinese Journal of New Drugs and Clinical Remedies
关键词
麦考酚酸酯
肾移植
免疫抑制剂
mycophenolate mofetil
kidney transplantation
immunosuppressive agents
azathioprine